

LISTING OF AFRICURE PHARMACEUTICALS ON THE SEM -- Africa health care under focus







Acting as Transaction Advisor, Perigeum Capital Ltd is pleased to be associated with the listing of Africure Pharmaceuticals Ltd ("Africure" or "the Company" or "the Group"), whose shares, namely 8,337,500 ordinary shares of no par value, will be listed on the Official Market of the Stock Exchange of Mauritius Ltd (the "SEM") on 18 January 2021 by way of introduction following approval by the Listing Executive Committee of the SEM on 29 December 2020.

Africure was incorporated on 17 March 2017 under the laws of the Republic of Mauritius and holds a Global Business Licence issued by the Financial Services Commission in accordance with the Financial Services Act 2007. The principal activity of the Company is investment holding of manufacturing assets in Sub Saharan Africa, trading & procurement of pharmaceutical products. The Group is also a manufacturer and distributor of essential pharmaceutical products for human consumption (e.g. antibiotics, anti-inflammatory, anti-diabetic, painkillers, anti-viral, anti-malaria drugs). The Company's mission revolves around the manufacture of essential pharmaceutical products in Africa, by Africans, for Africa. Africure has created local manufacturing capabilities in Cameroon, Namibia, Botswana, and Côte D'Ivoire and is in the process of expanding into Ethiopia, Angola, Congo in the very near future. The main objective of Africure is to solve persistent issues in Sub Saharan Africa relating to healthcare, such as affordability, availability, substandard quality, technological dependence, reliance on imports, foreign exchange deficiency.

In the wake of the Covid-19 pandemic, while the healthcare sector has grown in both prominence and relevance worldwide a growing need to build self-sufficiency and cost-efficiency for medication in Africa is also being critically felt. It is expected that the listing on SEM will provide access to a global investor base of banks, asset managers, high net worth individuals and other sources of capital who all view Mauritius as an attractive investment destination.



Perigeum Capital Ltd has positioned itself to assist companies which operate with a sense of purpose for the betterment of the African continent by providing relevant and reliable advice to enable those types of entities to achieve a 'listing-ready' status in view of further growth and development. In this regard, acting as Transaction Advisor, Perigeum Capital managed the whole listing process ranging from professional advice to Africure for the implementation of changes required pre-listing, to preparing the Company for listing, including a corporate structure review and the setting up a corporate governance framework. While Perigeum Capital was also responsible for liaising with and obtaining necessary clearances from the different stakeholders, it also steered the Company towards securing approval for its listing on the SEM including drafting documents, namely Listing Particulars and other documentation, and review of the valuation report.

As SEM Authorised Representative and Sponsor of Africure, Perigeum Capital shall advise the Company with regards to its future compliance and continuing obligations with the SEM, including the Company's intention to proceed with various placings subsequent to its listing on the SEM.

DISCLAIMER

The information in this newsletter was prepared by Perigeum Capital to inform partners about the listing of Africure on the SEM. All information contained in this announcement are already available in the public domain. This newsletter is not an invitation to the public to subscribe for shares in the Company and is provided for information purposes only. While all reasonable care has been taken in the preparation of this newsletter, Perigeum Capital accepts no responsibility for any errors it may contain, whether caused by negligence or otherwise, or for any loss, however caused, sustained by any person that relies on it. If you do not wish to receive further information from Perigeum Capital, please send an email to info@perigeum.mu.